7Baggers
 Published on: 2025-11-16 18:05:52  newser.com Mon, 17 Nov 2025 00:05:52 GMT
 Fate Therapeutics (FATE) Receives a Hold from Bank of America Securities  The Globe and Mail Sun, 16 Nov 2025 18:02:27 GMT
 Fate Therapeutics: Q3 Earnings Snapshot  CTPost Fri, 14 Nov 2025 06:19:03 GMT
 Fate Therapeutics earnings beat by $0.03, revenue topped estimates  Investing.com Nigeria Fri, 14 Nov 2025 01:29:37 GMT
 Fate Therapeutics (FATE) Tops Q3 EPS by 3c  StreetInsider Thu, 13 Nov 2025 21:35:12 GMT
 Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating  富途牛牛 Thu, 13 Nov 2025 19:32:00 GMT
 Fate Therapeutics earnings beat by $0.03, revenue topped estimates  Investing.com India Thu, 13 Nov 2025 18:52:33 GMT
 Automated trading signals detected on Fate Therapeutics Inc.  newser.com Thu, 13 Nov 2025 16:13:01 GMT
 td cowen maintains fate therapeutics(fate.us) with hold rating  富途牛牛 Thu, 13 Nov 2025 15:33:00 GMT
 Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates  Yahoo Finance Thu, 13 Nov 2025 14:40:02 GMT
 Fate Therapeutics reports Q3 EPS (27c), consensus (28c)  TipRanks Thu, 13 Nov 2025 13:59:38 GMT
 Fate Therapeutics: Q3 Earnings Snapshot  San Francisco Chronicle Thu, 13 Nov 2025 13:53:57 GMT
 FATE THERAPEUTICS INC SEC 10-Q Report  TradingView Thu, 13 Nov 2025 13:43:00 GMT
 Fate Therapeutics Q3 net loss widens  TradingView Thu, 13 Nov 2025 13:38:13 GMT
 Q3 Earnings Estimate for FATE Issued By HC Wainwright  MarketBeat Mon, 03 Nov 2025 08:00:00 GMT
 HC Wainwright & Co. Upgrades Fate Therapeutics (FATE)  Nasdaq Fri, 31 Oct 2025 07:00:00 GMT
 fate therapeutics shares rise after hc wainwright upgrade  MarketScreener Fri, 31 Oct 2025 07:00:00 GMT
 Q3 Earnings Forecast for Fate Therapeutics Issued By Wedbush  MarketBeat Thu, 30 Oct 2025 07:00:00 GMT
 3 cancer-focused stocks showing strong pipeline progress  TradingView Tue, 28 Oct 2025 07:00:00 GMT
 layoff tracker: ferring will lay off 64 employees in new jersey  BioSpace Tue, 28 Oct 2025 07:00:00 GMT

Fate Therapeutics, Inc
(NASDAQ:FATE) 

FATE stock logo

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, ...

Founded: 2007
Full Time Employees: 178
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends